{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:46:13Z","timestamp":1771512373767,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Hyperviscosity syndrome (HVS) is a significant complication in Waldenstr\u00f6m's macroglobulinemia (WM), although the significance of plasmapheresis in clinical practice has not been clarified. To confirm the efficacy and safety of plasmapheresis followed by primary therapy for WM with HVS, we retrospectively conducted this study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Untreated WM with HVS, or serum immunoglobulin M (IgM) levels \u22654000\u2009mg\/dL, were analyzed. The basic therapeutic flow was conducted as follows: (1) performing plasmapheresis, (2) followed by primary therapy without rituximab, and (3) performing the second cycle. The serum IgM reduction rate and adverse events (AEs) were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ten patients were enrolled. The median serum IgM levels at diagnosis, post\u2010plasmapheresis, after the first cycle of primary therapy, and after the second cycle were 5174, 2900, 3286, and 2657\u2009mg\/dL, respectively. No patients experienced IgM flare or bleeding AEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The therapeutic flow offers sufficient efficacy and safety in WM with HVS.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1744-9987.14094","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T09:03:10Z","timestamp":1702112590000},"page":"417-423","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of therapeutic procedure for Waldenstr\u00f6m's macroglobulinemia with hyperviscosity syndrome"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5882-7631","authenticated-orcid":false,"given":"Kenichi","family":"Ito","sequence":"first","affiliation":[{"name":"Hematology Division National Hospital Organization Disaster Medical Center  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Nephrology Division National Hospital Organization Disaster Medical Center  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Hirano","sequence":"additional","affiliation":[{"name":"Laboratory and Pathology Division National Hospital Organization Disaster Medical Center  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9860-8257","authenticated-orcid":false,"given":"Naohiro","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Hematology Division National Hospital Organization Disaster Medical Center  Tokyo Japan"},{"name":"Clinical Research Division National Hospital Organization Disaster Medical Center  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,12,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347690"},{"issue":"1","key":"e_1_2_9_4_1","first-page":"802","article-title":"Acquired Von Willebrand disease in patients with Waldenstr\u00f6m macroglobulinemia","volume":"130","author":"Castillo JJ","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-388256"},{"key":"e_1_2_9_6_1","unstructured":"National Cancer Institute.NCCN clinical practice guidelines in oncology. Waldenstrom macroglobulinemia\/lymphoplasmacytic lymphoma. Version 2.2022. [cited 2022 February 6]. Available from:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/waldenstroms.pdf"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21705"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02730-x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30224-6"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20658"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh403"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-174359"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.13548"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21655"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-846816"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000725"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12102"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2017.08.010"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-565135"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.5045\/br.2018.53.2.117"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4677"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14561"},{"issue":"5","key":"e_1_2_9_23_1","first-page":"335","article-title":"Hyperviscosity syndrome: efficacy and comparison of plasma exchange by plasma separation and cascade filtration in patients with immunocytoma of Waldenstrom's type","volume":"43","author":"Hoffkes HG","year":"1995","journal-title":"Clin Nephrol"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410220612"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.14094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T01:00:47Z","timestamp":1714352447000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1744-9987.14094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,9]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/1744-9987.14094"],"URL":"https:\/\/doi.org\/10.1111\/1744-9987.14094","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,9]]},"assertion":[{"value":"2023-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}